Safety and Efficacy of KSVCBD Injection in Autoimmune Diseases

Summary

KSVCBD injection is an in vivo Chimeric Antigen Receptor T-Cell (CAR-T cell) therapy product. This single-arm, open-label, early exploratory clinical study is designed to evaluate the safety and preliminary efficacy of KSVCBD injection in patients with Autoimmune Diseases.

Timeline

Start

2026-06-01

Primary completion

2028-12-31

Completion

2029-03-31

Drugs

Indications